People with these disorders can be paranoid and have difficulty being understood by others, as they often have odd or eccentric modes of speaking and an unwillingness and inability to form and maintain close relationships. Though their perceptions may be unusual, these anomalies are distinguished from delusions or hallucinations as people with these would be diagnosed with other conditions. Significant evidence suggests a small proportion of people with Cluster A personality disorders, especially schizotypal personality disorder, have the potential to develop schizophrenia and other psychotic disorders. These disorders also have a higher probability of occurring among individuals whose first-degree relatives have either schizophrenia or a Cluster A personality disorder. Paranoid personality disorder: characterized by a pattern of irrational suspicion and mistrust of others, interpreting motivations as malevolent. Schizoid personality disorder: lack of interest and detachment from social relationships, apathy, and restricted emotional expression. Schizotypal personality disorder: pattern of extreme discomfort interacting socially, and distorted cognition and perceptions. Cluster B (dramatic, emotional or erratic disorders)
Cluster B personality disorders are characterized by impulsive, self-destructive, emotional behavior and sometimes incomprehensible interactions with others. Antisocial personality disorder: pervasive pattern of disregard for and violation of the rights of others, lack of empathy, bloated self-image, manipulative and impulsive behavior. Borderline personality disorder: pervasive pattern of abrupt emotional outbursts, altered empathy, instability in relationships, self-image, identity, behavior and affect, often leading to self-harm and impulsivity. Histrionic personality disorder: pervasive pattern of attention-seeking behavior, excessive emotions, and egocentrism.
Lusutrombopag, sold under the brand name Mulpleta among others, is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures. It is being manufactured and marketed in Japan by Shionogi. It was approved by the U.S. Food and Drug Administration (FDA) in July 2018, and NICE in January 2020.It was approved for medical use in the European Union in February 2019. References
External links
"Lusutrombopag". Drug Information Portal. U.S. National Library of Medicine.